Edwards Lifesciences Corp reports $6.07 billion revenue for fiscal year ended December 31, 2025, up 11.5%

ยท EW

Edwards Lifesciences Corp reported revenue of $6.07 billion for the year ended December 31, 2025, an increase of 11.5% from the previous year ($5.44 billion).

For the same period it posted net income of $1.07 billion, down 74.3%, or $1.83 per diluted share (6.97 a year earlier).

That is a net margin of 17.7%.

On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Edwards Lifesciences Corp news